Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...

During the past decade, partnerships were the most frequent type of deal in North America and Asia-Pacific. Meanwhile, in Europe, mergers and licensing agreements contributed to an equal number of ...

One thing that sticks with me is how earnest the documentary feels. Steen was both a dear and considerate friend to the ...

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.

Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals ARWR.

New Gene Therapy for Muscular Dystrophy Offers Hope July 17, 2024 — A new gene therapy treatment for Duchenne muscular dystrophy (DMD) shows promise of not only arresting the decline of the ...

This Friday, November 29, the Spirit of Christmas concert returns to Belfast for a sixth year to raise money for Muscular ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Columnist Patrick Moeschen, who lives with limb-girdle muscular dystrophy, explains why controlling what he can is so ...

2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...

the treatment restored large therapeutic muscle proteins to normal levels, the researchers reported. Specifically, StitchR restored the protein Dystrophin, which is absent in patients with Duchenne ...

These are among the recent developments for Sarepta Therapeutics. As Sarepta Therapeutics (NASDAQ:SRPT) navigates the competitive landscape of Duchenne muscular dystrophy treatments, InvestingPro data ...